There was a broker meeting at the Zenith Epigenetics Ltd offices in Calgary on 23 Feb. It was actually an RVX meeting but there were a couple of comments about Zenith so I will post them here.

The Phase I CRPC trial continues. They are still on the first cohort of the ZEN3694 and Enzalutamide combination. They are very encouraged as to the results they are getting so far. The longest dosed patient on ZEN3694 is now 7 months. The next phase of this trial after this current combination is finished, will be in combination with a breast cancer drug. They have been in conversations with a company that is considering doing a combination trial with a lung cancer drug. Money is not an issue at this time as they were financed last year and the coffers have plenty in them at this time.

These notes were put together after talking with 3 people who were at this meeting. If you know of someone who was at the meeting and made notes please post them if you can.

tada